Search Results
Maimonides Institute for Biomedical Research of Cordoba (IMIBIC); Reina Sofia University Hospital, Córdoba, Spain
Search for other papers by Aura D Herrera-Martínez in
Google Scholar
PubMed
Search for other papers by Leo J Hofland in
Google Scholar
PubMed
Search for other papers by María A Gálvez Moreno in
Google Scholar
PubMed
Search for other papers by Justo P Castaño in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
Search for other papers by Richard A Feelders in
Google Scholar
PubMed
progression and guide an optimal treatment ( Oberg et al . 2015 ). An ideal biomarker should have a high sensitivity for the diagnosis of NENs, to predict tumor clinical behavior and for the response to treatment ( Turner et al . 2006 ). To date, only few
Search for other papers by Mojun Zhu in
Google Scholar
PubMed
Search for other papers by Karl R Sorenson in
Google Scholar
PubMed
Search for other papers by Rebecca Liu in
Google Scholar
PubMed
Search for other papers by Bonnie E Gould Rothberg in
Google Scholar
PubMed
Search for other papers by Thorvardur R Halfdanarson in
Google Scholar
PubMed
limited. Here, we sought to assess the evidence and clinical applications of proposed, prognostic biomarkers in PNETs by evaluating existing publications according to robust sampling, laboratory, and statistical methods. Materials and methods
Search for other papers by Diana Lim in
Google Scholar
PubMed
Cancer Genetics Service, Division of Medical Oncology, National Cancer Centre, Singapore, Singapore
Search for other papers by Joanne Ngeow in
Google Scholar
PubMed
defects in the other genes involved in HR. Therefore, the utility of PARPi in cancer therapeutics is potentially greater than what was initially envisioned. Table 1 Clinical trials incorporating molecular biomarkers to select patients for PARP
Search for other papers by F M Brouwers in
Google Scholar
PubMed
Search for other papers by E F Petricoin III in
Google Scholar
PubMed
Search for other papers by L Ksinantova in
Google Scholar
PubMed
Search for other papers by J Breza in
Google Scholar
PubMed
Search for other papers by V Rajapakse in
Google Scholar
PubMed
Search for other papers by S Ross in
Google Scholar
PubMed
Search for other papers by D Johann in
Google Scholar
PubMed
Search for other papers by M Mannelli in
Google Scholar
PubMed
Search for other papers by B L Shulkin in
Google Scholar
PubMed
Search for other papers by R Kvetnansky in
Google Scholar
PubMed
Search for other papers by G Eisenhofer in
Google Scholar
PubMed
Search for other papers by M M Walther in
Google Scholar
PubMed
Search for other papers by B A Hitt in
Google Scholar
PubMed
Search for other papers by T P Conrads in
Google Scholar
PubMed
Search for other papers by T D Veenstra in
Google Scholar
PubMed
Search for other papers by D P Mannion in
Google Scholar
PubMed
Search for other papers by M R Wall in
Google Scholar
PubMed
Search for other papers by G M Wolfe in
Google Scholar
PubMed
Search for other papers by V A Fusaro in
Google Scholar
PubMed
Search for other papers by L A Liotta in
Google Scholar
PubMed
Search for other papers by K Pacak in
Google Scholar
PubMed
validation in prospective cohort studies the measurement of these biomarkers might ultimately be used in clinical practice together with other markers for metastatic pheochromocytoma, so that the combined positive-predictive value will be high enough to
St Vincent’s Clinical School, UNSW Sydney, Sydney, New South Wales, Australia
Search for other papers by H H Milioli in
Google Scholar
PubMed
Search for other papers by S Alexandrou in
Google Scholar
PubMed
St Vincent’s Clinical School, UNSW Sydney, Sydney, New South Wales, Australia
Search for other papers by E Lim in
Google Scholar
PubMed
St Vincent’s Clinical School, UNSW Sydney, Sydney, New South Wales, Australia
Search for other papers by C E Caldon in
Google Scholar
PubMed
resistance is also now emerging as a significant clinical problem, and there are not yet effective biomarkers for the emergence of resistance ( Portman et al. 2019 ). Both CCNE1 and CCNE2 have been identified as potential biomarkers that alter
Search for other papers by Bethany Smith in
Google Scholar
PubMed
Search for other papers by Priyanka Agarwal in
Google Scholar
PubMed
Greater Los Angeles Veterans Administration, Los Angeles, California, USA
Search for other papers by Neil A Bhowmick in
Google Scholar
PubMed
inhibitors in the armamentarium against cancer has caused us to reevaluate our understanding of T cell biology, in terms of clinical applications. Now, companion biomarkers and combination therapy candidates are a focus in many labs. miRs can play an
Search for other papers by Marion T Weigel in
Google Scholar
PubMed
The Institute of Cancer Research, Royal Marsden Hospital, Breakthrough Breast Cancer Research Centre, 237 Fulham Road, London SW3 6JB, UK
Search for other papers by Mitch Dowsett in
Google Scholar
PubMed
determined. In this review, we discuss the importance of established prognostic factors and predictive biomarkers as well as some emerging biomarkers that are currently undergoing testing for technical validity and clinical utility. Prognosis and prediction
Search for other papers by James Yao in
Google Scholar
PubMed
Search for other papers by Abhishek Garg in
Google Scholar
PubMed
Search for other papers by David Chen in
Google Scholar
PubMed
Search for other papers by Jaume Capdevila in
Google Scholar
PubMed
Search for other papers by Paul Engstrom in
Google Scholar
PubMed
Search for other papers by Rodney Pommier in
Google Scholar
PubMed
Search for other papers by Eric Van Cutsem in
Google Scholar
PubMed
Search for other papers by Simron Singh in
Google Scholar
PubMed
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
Search for other papers by Wei He in
Google Scholar
PubMed
Search for other papers by Markus Riester in
Google Scholar
PubMed
Search for other papers by Parul Patel in
Google Scholar
PubMed
Search for other papers by Maurizio Voi in
Google Scholar
PubMed
Search for other papers by Michael Morrissey in
Google Scholar
PubMed
Search for other papers by Marianne Pavel in
Google Scholar
PubMed
Search for other papers by Matthew Helmut Kulke in
Google Scholar
PubMed
–Mann–Whitney test. Cox proportional hazard model and log-rank tests were used to assess the association between groups defined by genomic biomarkers and clinical outcome. GI NET from RADIANT-2 and RADIANT-4 trials were pooled together for correlative analysis, and
Search for other papers by Nely Díaz-Mejía in
Google Scholar
PubMed
Search for other papers by David García-Illescas in
Google Scholar
PubMed
Search for other papers by Rafael Morales-Barrera in
Google Scholar
PubMed
Search for other papers by Cristina Suarez in
Google Scholar
PubMed
Search for other papers by Jacques Planas in
Google Scholar
PubMed
Search for other papers by Xavier Maldonado in
Google Scholar
PubMed
Search for other papers by Joan Carles in
Google Scholar
PubMed
Search for other papers by Joaquin Mateo in
Google Scholar
PubMed
selection biomarker mutations in any of 14 genes ( BRCA1, BRCA2, ATM , BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L ); which represent all but one (PPP2R2A) genes included in the clinical trial companion
Department of Medical Oncology, University of Sydney, Cancer Research Program, Sydney Cancer Centre, Missenden Road, Camperdown, New South Wales 2050, Australia
Department of Medical Oncology, University of Sydney, Cancer Research Program, Sydney Cancer Centre, Missenden Road, Camperdown, New South Wales 2050, Australia
Search for other papers by Kate L Mahon in
Google Scholar
PubMed
Search for other papers by Susan M Henshall in
Google Scholar
PubMed
Search for other papers by Robert L Sutherland in
Google Scholar
PubMed
Department of Medical Oncology, University of Sydney, Cancer Research Program, Sydney Cancer Centre, Missenden Road, Camperdown, New South Wales 2050, Australia
Department of Medical Oncology, University of Sydney, Cancer Research Program, Sydney Cancer Centre, Missenden Road, Camperdown, New South Wales 2050, Australia
Search for other papers by Lisa G Horvath in
Google Scholar
PubMed
, inhibition of clusterin expression enhances docetaxel sensitivity ( Patterson et al . 2006 ). In vivo , LNCaP xenografts that overexpress clusterin are less responsive to paclitaxel than controls ( Miyake et al . 2000 d ). Clinically, sCLU expression is